With mRNA proof of concept on display in Covid-19, Moderna plots HIV vaccine moonshot as part of pipeline expansion
Moderna’s march from early herald of mRNA to savior in the fight against Covid-19 has been a sight to behold as better-funded competitors in the race for a vaccine have fallen by the wayside. Now, with its proof of concept validated, Moderna is adding to its aggressive R&D plan and looking to break ground along the way.
With an FDA emergency use authorization for its mRNA-based Covid-19 vaccine showing promise for its once-unlikely mechanism of action, Moderna is expanding its ever-growing pipeline, which now includes two long-shot tries at HIV, the company said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.